KR920004818B1 - Skin care composition - Google Patents
Skin care composition Download PDFInfo
- Publication number
- KR920004818B1 KR920004818B1 KR1019890017275A KR890017275A KR920004818B1 KR 920004818 B1 KR920004818 B1 KR 920004818B1 KR 1019890017275 A KR1019890017275 A KR 1019890017275A KR 890017275 A KR890017275 A KR 890017275A KR 920004818 B1 KR920004818 B1 KR 920004818B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- free radicals
- curcumin
- sod
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음.No content.
Description
이 발명은 동물의 세포를 보호하는 제제에 관한 것으로 특히 생약 제제인 울금(Cureuma ionga L.)의 쿠르쿠미노이드(Curcuminoids)성분과 효소의 일종인 SOD(svperoxide dismvtase) 또는 아스코르빈산(ascorbic acid)를 함유하며, 특히 유해한 활성 산소류(actiuated oxygen species)로부터 세포를 보호하는 탁월한 활성을 가지며, 특히 빛에 노출이 많은 피부 세포를 보호하는 화장품의 원료로써 유용한 세포보호제에 관한 것이다.TECHNICAL FIELD The present invention relates to a preparation for protecting a cell of an animal. In particular, a curcuminoids component of curcuma ionga L., which is a herbal preparation, and an SOD (svperoxide dismvtase) or ascorbic acid, which is a kind of enzyme, In particular, the present invention relates to a cytoprotective agent which has excellent activity of protecting cells from particularly harmful oxygen species, and is particularly useful as a raw material of cosmetics for protecting skin cells exposed to light.
세포 보호제는 유해한 활성 산소류로부터 세포를 보호하는 제제로서 활성 산소류는 지질, 단백질, 헥산등의 생체 물질을 변질시켜 돌연변이, 발암, 노화의 원인이 되기 때문에(Leibouits, B.E.and Siegel, B.W. (1980), J.Geontel., 35 : 45)세포 보호제는 돌연변이, 발암, 노화의 원인을 근본적으로 제거하는 우수성을 갖는다.Cytoprotectants are agents that protect cells from harmful free radicals. These free radicals alter biological materials such as lipids, proteins, and hexanes, causing mutations, carcinogenesis, and aging (Leibouits, BEand Siegel, BW (1980). ), J.Geontel., 35:45) Cell protectors have the superiority to fundamentally eliminate the causes of mutations, carcinogenesis and aging.
생체에서 생성되는 활성 산소류로는1O2, O- 2, H2O2등이 있으며 이들은 생체내의 각종 효소반응에 의해 생성되어 생리활성 물질의 생합성, 면역기능, 약물의 대사등에서 매우 중요한 역할을 하지만 그 반응성이 매우 커서 이들이 과잉생성될 경우에는 오히려 생체에 손상을 가져올 수 있다.The active oxygen species generated in the living body include 1 O 2 , O - 2 , H 2 O 2 , and these are produced by various enzyme reactions in the living body, and play an important role in biosynthesis, immune function, and metabolism of bioactive substances. However, since the reactivity is very large, if they are overproduced, they may cause damage to the living body.
한편 활성 산소류는 빛과 광증감 작용을 갖는 각종 약물로 인해서도 생성될 수 있는데 현대사회에서 각종 약물에 대한 접촉이 많아지면서 과잉의 유기 자유 라디칼과 활성 산소류에 의한 생체 폐해가 우려되는 실정이다.On the other hand, free radicals can be generated by various drugs having light and photosensitizing effects. In modern society, the contact with various drugs increases, causing the possibility of biohazard caused by excess organic free radicals and free radicals. .
그러나 아직까지는 이렇다할 세포 보호제가 나와 있지 않은 실정이며, 산화 방지제인 α-토코페롤이 세포 보호제로서 쓰이고 있는 예는 있으나 그 실질적 효능은 의심받고 있는 실정이다. 이에 강력한 세포 보호제의 필요성을 절실히 파악하게 된 발명자는 1차적으로 세포 보호제를 검색할 목적으로 유해한 활성 산소류로부터 세포를 보호하는 활성을 간단하고 정확하게 측정하는 방법을 정립한 바 있으며, 2차적으로 각종 식물의 유용성분, 특히 강력한 항산화 효과가 보고되고 있는 성분들을 중심으로하여 검색 연구를 계속하여 오고 있다.However, there is no cell protection agent yet, and there is an example in which the antioxidant α-tocopherol is used as a cell protection agent, but its actual efficacy is doubted. Therefore, the inventors who have grasped the necessity of powerful cytoprotective agents have established a simple and accurate method of measuring the activity of protecting cells from harmful free radicals for the purpose of searching for cellular protective agents. Research has been conducted on the useful components of plants, especially those whose strong antioxidant effects are reported.
[표 1]TABLE 1
그 결과로 생약제제인 울금의 쿠르쿠미노이드 성분(표 1)인 쿠르쿠민(curcumin), HCFM(4-hydroxy cinnamoly(feruloyl) methane), BHCM(bis(4-hydroxy cinnamoyl) methane)등이 유해한 활성 산소류로부터 세포를 보호하는 활성이 매우 강력함을 밝혀내었다(표 2).As a result, curcumin (curcumin), HCFM (4-hydroxy cinnamoly (feruloyl) methane), BHCM (bis (4-hydroxy cinnamoyl) methane), etc. It was found that the activity of protecting cells from cells is very potent (Table 2).
[표 2]TABLE 2
울금은 인도, 서부 파키스탄, 남부 중국, 말레이지아등에서 재배되는 다년초로서 생강과에 속하며 생약으로서 이담제, 건위제등으로 사용되고 있으며 그 주성분은 쿠르쿠미노이드로서 쿠르쿠민, HCFM, BHCM 등이 있다. 이들 쿠르쿠미노이드 성분은 주황색의 식용 색소로 이용되고 있는 안전성이 매우 높은 물질이며 쿠르쿠민은 항염증작용(R.C.SRIMAL and B.N.DHAWAN, J.Pharm.Pharmc(1973), 25 ; 447-452)도 보고되어 있다.Turmeric is a perennial plant cultivated in India, western Pakistan, southern China, Malaysia, etc. It belongs to ginger family and is used as an herbal medicine and wit, and its main ingredients are curcuminoids, curcumin, HCFM, and BHCM. These curcuminoids are highly safe substances used as orange food colorings, and curcumin has been reported to have anti-inflammatory effects (RCSRIMAL and BNDHAWAN, J. Pharm. Pharmc (1973), 25; 447-452). have.
본 발명자는 쿠르쿠미노이드 성분이 유해한 활성 산소류로부터 세포를 보호하는 활성이 강력한 것이 항염증 작용과 밀접한 관련이 있는 것으로 판단하고 있다.The inventors believe that the strong activity of curcuminoid components to protect cells from harmful free radicals is closely related to anti-inflammatory action.
한편 본 발명자는 쿠르쿠미노이드 성분이 유해한 활성 산소류로부터 세포를 보호하는 활성이 아스코르빈산의 첨가로 급격히 증대될 것으로 예측하여 여러가지로 실험한 결과 표 3에 기재한On the other hand, the present inventors have predicted that the curcuminoid component will rapidly increase the activity of protecting cells from harmful active oxygen species by addition of ascorbic acid.
[표 3]TABLE 3
바와 같이 아스코르빈산이 쿠르쿠민의 산화를 방지함으로써 상승적으로 세포를 보호하는 것으로 밝혀냈다. 즉 25μM의 쿠르쿠민에 대해 아스코르빈산을 100μM 첨가하였을 때 유해한 활성 산소류로부터 세포를 보호하는 활성이 급격히 증대되었다.Ascorbic acid was found to synergistically protect cells by preventing the oxidation of curcumin. That is, when 100 μM of ascorbic acid was added to 25 μM of curcumin, the activity of protecting cells from harmful free radicals rapidly increased.
한편 발명자는 쿠르쿠미노이드 성분이 유해한 활성 산소류로부터 세포를 보호하는 활성이 SOD의 첨가로 급격히 증대될 것으로 예측하고 실험하였다.On the other hand, the inventors anticipated and experimented that the curcuminoid component would dramatically increase the activity of protecting cells from harmful free radicals by the addition of SOD.
SOD는 생물체의 세포질이나 미토콘드리아에 존재하며 유해한 활성 산소인1O2를 제거함으로써 산화적 손상으로부터 세포를 보호하는 효소이다.SOD is an enzyme that exists in the cytoplasm and mitochondria of organisms and protects cells from oxidative damage by eliminating the harmful free radicals 1 O 2 .
본 발명에서 유해한 활성 산소류로부터 세포를 보호하는 활성의 측정에 있어서 로즈벵갈(rose-bengal)을 광증감제로 이용하였는데 로즈벵갈은 광조사로1Og를 생성한다고 알려져 있다.For the measurement of the activity of protecting cells from the harmful free radicals from the current invention Rose Bengal (rose-bengal) were used to zero photosensitizer Rose Bengal is known to generate 1 O g of a light irradiation.
발명자는 쿠르쿠미노이드 성분이 유해한 활성 산소인1O2를 보다 덜 해로운 O- 2로 변환시킴으로써 세포를 보호하고 SOD는 다시 O- 2를 제거함으로써 세포를 상승적으로 보호할 것으로 예측하고 이를 실험한 바 표 4에 기재한 바와 같이 입증되었다.The inventors predicted and experimented that the curcuminoid component would protect the cells by converting the harmful free radicals 1 O 2 into less harmful O - 2 and the SOD would synergistically protect the cells by removing O - 2 again. Proven as described in Table 4.
[표 4]TABLE 4
즉 25μM의 쿠르쿠미노이드에 대해 SOD를 50-100μg/ml 첨가하였을 때 유해한 활성 산소류로부터 세포를 보호하는 활성이 급격히 증대되었다.That is, when SOD was added to 50-100 µg / ml against the curcuminoid of 25 µM, the activity of protecting the cells from harmful free radicals rapidly increased.
이 발명은 이러한 연구 결과를 토대로 하여 쿠르쿠미노이드와 SOD 또는 아스코르빈산을 함유하는 세포보호제에 관한 것으로, 특히 빛에 노출이 많아서 활성 산소류로부터 피해를 입기 쉬운 피부 세포를 보호하는 제제로서 보다 큰 가치를 가질 수 있으며 특히 화장품의 원료로서 중요한 가치를 지닌다.Based on these findings, the present invention relates to a cytoprotective agent containing curcuminoids and SOD or ascorbic acid. In particular, the present invention relates to a cytoprotective agent that protects skin cells susceptible to damage from free radicals due to high exposure to light. It can have value and is of particular value as an ingredient in cosmetics.
본 발명을 상세히 설명하면 울금의 쿠르쿠미노이드 성분, 구체적으로는 쿠르쿠민, HIFM, BHCM중에서 적어도 하나를 택하고 그것을 SOD 또는 아스코르빈산과 조합한 조성물로서의 세포 보호제에 관한 것이다.DETAILED DESCRIPTION OF THE INVENTION The present invention relates in detail to cell protective agents as compositions wherein the curcuminoid component of turmeric, specifically curcumin, HIFM, BHCM, is selected and combined with SOD or ascorbic acid.
본 발명에서 상기 두가지 유효성분의 조성비율은 구체적으로 한정되는 것은 아니지만 본 발명의 조성비율을 예를들어 설명하면 SOD 8g 또는 아스코르빈산 2.8g(16.0mmole)을 물 1.0리터에 용해시키고 여기에 쿠르쿠민 1.48g(4.0mmol), HCFM 1.36g(4.0mmole) 또는 BHCM 1.24g(4.0mmole)을 에탄올 20ml에 용해시킨 액을 첨가하고 혼화하여 세포 보호제를 제조한다. 이 발명의 세포 보호제는 유해한 활성 산소류로부터 세포를 보호하는 활성이 매우 강력했다.In the present invention, the composition ratio of the two active ingredients is not specifically limited. For example, the composition ratio of the present invention is dissolved in 1.0 liter of water with 8 g of SOD or 2.8 g (16.0 mmole) of ascorbic acid and curcumin. 1.48 g (4.0 mmol), HCFM 1.36 g (4.0 mmol) or BHCM 1.24 g (4.0 mmol) dissolved in 20 ml of ethanol was added and mixed to prepare a cell protective agent. The cytoprotective agent of this invention was very strong in protecting cells from harmful free radicals.
다음의 실시예로 이 발명을 보다 더 상세히 설명하겠다.The following examples illustrate the invention in more detail.
[실시예 1]Example 1
쿠르쿠민 1.48g(4.0mmole)을 에탄올 20ml에 용해하고, 따로 SOD 8g을 물 1.0리터에 용해한 후 두 용액을 서로 합하여 세포 보호제를 제조하였다.1.48 g (4.0 mmol) of curcumin was dissolved in 20 ml of ethanol, and 8 g of SOD was dissolved in 1.0 liter of water, and then the two solutions were combined with each other to prepare a cell protective agent.
[실시예 2]Example 2
HCFM 1.36g(4.0mmole)을 에탄올 20ml에 용해하고, 따로 아스코르빈산 2.8g(16mmole)을 물 1.0리터에 용해한 후 두 용액을 서로 합하여 세포 보호제를 제조하였다.1.36 g (4.0 mmol) of HCFM was dissolved in 20 ml of ethanol. Separately, 2.8 g (16 mmol) of ascorbic acid was dissolved in 1.0 liter of water, and the two solutions were combined with each other to prepare a cell protective agent.
[실시예 3]Example 3
BHCM 1.24g(4.0mmole)을 에탄올 20ml에 용해하고, 따로 SOD 8g을 물 0.5리터에 용해하고, 따로 아스코르빈산 2.8g(16mmole)을 물 1.0리터에 용해한 후 세 용액을 모두 합하여 세포 보호제를 제조하였다.1.24 g (4.0 mmol) of BHCM was dissolved in 20 ml of ethanol, 8 g of SOD was dissolved in 0.5 liter of water, and 2.8 g (16 mmol) of ascorbic acid was dissolved in 1.0 liter of water. It was.
[실시예 4]Example 4
쿠르쿠민, HCFM 또는 BHCM 4.0mmole을 각각 에탄올 1.0리터에 녹여서 각각 세포 보호제를 제조하였다.A cell protective agent was prepared by dissolving curcumin, HCFM or BHCM 4.0 mmol in 1.0 liter of ethanol, respectively.
[실시예 7-8]Example 7-8
SOD 8g 또는 아스코르빈산 2.8g(16mmole)을 각각 물 1.0리터에 녹여서 각각 세포 보호제를 제조하였다.A cell protective agent was prepared by dissolving 8 g of SOD or 2.8 g (16 mmoles) of ascorbic acid in 1.0 liter of water, respectively.
[비교예 1]Comparative Example 1
α-토코페롤 4.0mmole을 에탄올 1.0리터에 녹여서 세포 보호제를 제조하였다.A cell protective agent was prepared by dissolving α-tocopherol 4.0 mmol in 1.0 liter of ethanol.
[시험 1][Exam 1]
세포 보호제가 활성 산소류로부터 세포를 보호하는 활성을 비교Cell protective agents compare the activity of protecting cells from free radicals
토끼로부터 채취된 혈액을 원심분리(3000rpm, 5분)하고 세척하여 얻은 적혈구를 생리 식염수에 희석하여 적혈구 현탁액(적혈구 6천만개/3.5ml)을 조제하였다. 직경 1.0cm의 10ml들이 파이렉스 시험관 6개를 준비하여 각각에 적혈구 현탁액 3.5ml씩을 넣었다. 6개의 시험관중 3개는 대조군으로서 에탄올 50μl씩을 첨가하고, 나머지 3개는 처리군으로서 세포 보호제를 50μl씩 첨가하고 암소에서 30분간 융화시켰다. 융화가 끝난 후, 광증감제로써 로즈벵갈(rose bergel)의 수용액(12μM) 0.5㎖를 첨가하고 입구를 파라필름으로 봉한 후 내부를 검게 칠한 50×20×25cm의 직육면체 상자안에 20w의 형광등을 장치하고, 형광등에서 5cm의 거리에 그 시험관을 배열시키고 15분간 광조사하였다. 강증감제를 첨가하고 광조사하는 것은 활성 산소류를 생성시키기 위한 것이다. 광조사가 끝난 후 그 시험관들을 암소에 두면서 15분간 간격으로 700mm에서의 투광도를 측정하였다. 이 파장에서 적혈구 현탁액의 투광도의 증가는 적혈구 용혈에 비례한다.Blood collected from rabbits was centrifuged (3000 rpm, 5 minutes), and the red blood cells obtained by washing were diluted in physiological saline to prepare a red blood cell suspension (60 million red blood cells / 3.5 ml). Six 10 ml Pyrex test tubes with a diameter of 1.0 cm were prepared, and 3.5 ml of red blood cell suspensions were added to each. Three of the six test tubes were added with 50 μl of ethanol as a control, the other three were added with 50 μl of cell protective agent as a treatment group and allowed to hydrate in the dark for 30 minutes. After the end of the melting, 0.5 ml of an aqueous solution of rose bergel (12 μM) was added as a photosensitizer, the inlet was sealed with parafilm, and a 20-watt fluorescent lamp was placed in a 50 × 20 × 25 cm rectangular box with a black interior. Then, the test tube was arranged at a distance of 5 cm from a fluorescent lamp and light irradiated for 15 minutes. The addition of light sensitizers and light irradiation are for generating active oxygen streams. After light irradiation, the test tubes were placed in the dark, and the light transmittance at 700 mm was measured at 15 minute intervals. The increase in the light transmittance of the red blood cell suspension at this wavelength is proportional to the red blood cell hemolysis.
이상의 모든 실험은 27℃이 항온실에서 실시하였으며 세포 보호제가 활성 산소류로부터 세포를 보호하는 활성은 이상의 측정 조건에서 첨가된 적혈구의 50%가 광용혈되는데 소요되는 시간(분)으로 정의하였다.All the above experiments were conducted in a constant temperature room at 27 ° C., and the activity of the cell protective agent to protect the cells from free radicals was defined as the time required for photohemolysis of 50% of the red blood cells added under the above measurement conditions.
그 결과를 표 4에 정리하였다.The results are summarized in Table 4.
이 발명의 세포 보호제들은 기존의 세포 보호제인 α-토코페롤에 비해 활성 산소류로부터 세포를 보호하는 활성이 매우 강력하였다.The cell protective agents of the present invention have a very strong activity of protecting cells from free radicals compared to the conventional cell protective agent α-tocopherol.
[표 5]TABLE 5
Claims (2)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019890017275A KR920004818B1 (en) | 1989-11-28 | 1989-11-28 | Skin care composition |
| FR9004524A FR2655054B1 (en) | 1989-11-28 | 1990-04-09 | CELL PROTECTIVE AGENTS CONTAINING CURCUMINOIDS. |
| JP2099462A JPH0714851B2 (en) | 1989-11-28 | 1990-04-17 | Cytoprotective agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019890017275A KR920004818B1 (en) | 1989-11-28 | 1989-11-28 | Skin care composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR910009279A KR910009279A (en) | 1991-06-28 |
| KR920004818B1 true KR920004818B1 (en) | 1992-06-18 |
Family
ID=19292122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019890017275A Expired KR920004818B1 (en) | 1989-11-28 | 1989-11-28 | Skin care composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPH0714851B2 (en) |
| KR (1) | KR920004818B1 (en) |
| FR (1) | FR2655054B1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531146T2 (en) | 1994-08-03 | 2004-06-03 | A.S.A.C. Pharmaceutical International, A.I.E. | METHOD FOR OBTAINING APOLAR AND POLAR EXTRACTS FROM TURKUMA AND THEIR APPLICATIONS |
| ES2081264B1 (en) * | 1994-08-03 | 1996-08-16 | A C Pharmaceutical Internation | PROCEDURE FOR OBTAINING APCOLAR AND POLAR EXTRACTS FROM CURCUMA AND APPLICATIONS THEREOF. |
| ATE227572T1 (en) * | 1995-07-14 | 2002-11-15 | Sabinsa Corp | LIFE-PROTECTING AGENTS, METHOD FOR USE THEREOF AND EXTRACTION METHOD FOR CUCUMINOIDS |
| WO1999055352A1 (en) * | 1998-04-29 | 1999-11-04 | Avon Products, Inc. | Skin whitening composition |
| WO2000051562A1 (en) * | 1999-03-03 | 2000-09-08 | Shiseido Company, Ltd. | Matrix metalloprotease inhibitor and utilization thereof |
| DE10029770A1 (en) * | 2000-06-16 | 2001-12-20 | Transmit Technologietransfer | Treatment of solid tumors, especially brain tumors, using curcumin or derivative to inhibit peritumoral edema and tumor growth and kill the tumor cells |
| JP3911991B2 (en) * | 2000-09-28 | 2007-05-09 | 株式会社ナリス化粧品 | Active oxygen scavenger and cosmetics |
| US20040223942A1 (en) * | 2003-03-06 | 2004-11-11 | Kao Corporation | Skin aging-preventing or improving agent |
| US7179841B2 (en) | 2004-01-13 | 2007-02-20 | L'oreal Usa Creative, Inc. | Stabilized ascorbic acid compositions and methods therefor |
| JP2007031315A (en) * | 2005-07-25 | 2007-02-08 | Pias Arise Kk | Transcription factor nrf2 activator and skin care preparation, cosmetic, and food and drink formulated with the transcription factor nrf2 activator |
| PL1993365T3 (en) * | 2006-03-06 | 2013-10-31 | Univ California | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders |
| US8192768B2 (en) | 2007-04-03 | 2012-06-05 | Laila Impex | Synergistic anti-inflammatory and antioxidant dietary supplement compositions |
| WO2009066303A2 (en) | 2007-11-22 | 2009-05-28 | Ganga Raju Gokaraju | New synergistic phytochemical composition for the treatment of obesity |
| WO2009080842A1 (en) * | 2007-12-21 | 2009-07-02 | Asac Compañía De Biotecnología E Investigación Sa | Photoprotective compositions |
| CN104147521A (en) * | 2014-08-19 | 2014-11-19 | 苏州卫生职业技术学院 | Traditional Chinese medicinal composition extract liquid and preparation method thereof |
-
1989
- 1989-11-28 KR KR1019890017275A patent/KR920004818B1/en not_active Expired
-
1990
- 1990-04-09 FR FR9004524A patent/FR2655054B1/en not_active Expired - Fee Related
- 1990-04-17 JP JP2099462A patent/JPH0714851B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR910009279A (en) | 1991-06-28 |
| JPH03170407A (en) | 1991-07-24 |
| FR2655054A1 (en) | 1991-05-31 |
| FR2655054B1 (en) | 1994-08-26 |
| JPH0714851B2 (en) | 1995-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920004818B1 (en) | Skin care composition | |
| Rao et al. | Hepatoprotective activity of Melia azedarach leaf extract against simvastatin induced Hepatotoxicity in rats | |
| Ma et al. | Coptis chinensis inflorescence and its main alkaloids protect against ultraviolet-B-induced oxidative damage | |
| Avdagić et al. | Spirulina platensis protects against renal injury in rats with gentamicin-induced acute tubular necrosis | |
| Lee et al. | Synthesis of phenolic amides and evaluation of their antioxidant and anti-inflammatory activity in vitro and in vivo | |
| Chidi et al. | In-vitro and In-vivo Antioxidant Activity of ethanol leaf Extract of Justicia carnea | |
| Babou et al. | Acute and subacute toxicity assessment of ethanolic extract of Rosmarinus officinalis in female Wistar rats | |
| Madubunyi et al. | In vitro and in vivo antioxidant potential of the methanolic extract of Cassia singueana Delile (Fabaceae) Lock leaves | |
| Jegadeeswari et al. | Quantification of total phenolics, flavonoid and in vitro antioxidant activity of Aristolochia bracteata Retz | |
| Semaming et al. | Antioxidant activity and protective effect against oxidative stress induced-hemolysis of Nymphaea lotus L. extracts | |
| KR970007186B1 (en) | Cell protectant for cosmetic use | |
| Ganesan et al. | In vitro Anti-inflammatory and Antioxidant Activity of Ormocarpum cochinchinense | |
| CN101824021A (en) | Method for extracting catechin small molecules in lotus root and application thereof | |
| KUMAR et al. | Henna (Lawsonia inermis) A medicinal herb effective in sickle cell disease | |
| Patel et al. | Cadmium induced oxidative stress-mediated pathophysiological alterations in chickens and their amelioration by polyherbal mixture enriched feed | |
| Menon et al. | Antioxidant and anti-inflammatory activities of the root of Mussaenda glabrata | |
| Uroko et al. | Evaluation of in vitro antioxidants activities, hepatoprotective and haematological effects of ethanol extract of Anthocleista vogelii stem bark (AVSB) on carbon tetrachloride (CCl4) induced rats | |
| Nizam et al. | Antioxidant activity of water and alcohol extracts of Thuja orientalis leaves | |
| Rao et al. | Antihyperglycemic and in vivo antioxidant activities of Phyllanthus watsonii A. shaw roots in streptozotocin induced type 2 diabetic rats | |
| Dermane et al. | Antisickling activity evaluation of fractions obtained from whole extracts of Newbouldia Laevis P. BEAUV (BIgnoniaceae) | |
| Sihotang et al. | Antioxidant Activity Test of Titanus (Leea aequata L) Leaf Extract with DPPH Method | |
| Rahman et al. | Antioxidant, anti-inflammatory and wound healing properties of ethanolic extracts of Thevetia peruviana (Pers.) K. Schum | |
| Dayana et al. | Antioxidant activity of ethanolic extract of Calotropis procera root in wistar rats | |
| Jagetia | Zairempuii. Detection of free radical scavenging activity of dhaura, anogeissus acuminata (roxb) wall ex bedd in vitro | |
| KR100800432B1 (en) | Namunjae Extract with Antioxidant Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
St.27 status event code: A-2-2-Q10-Q13-nap-PG1605 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 19990510 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20000619 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20000619 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |